摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methoxybenzenecarbothioic acid | 41118-62-1

中文名称
——
中文别名
——
英文名称
2-methoxybenzenecarbothioic acid
英文别名
o-Methoxythiobenzoesaeure;2-methoxythiobenzoic acid;o-methoxythiobenzoic acid;2-methoxybenzenecarbothioic S-acid
2-methoxybenzenecarbothioic acid化学式
CAS
41118-62-1
化学式
C8H8O2S
mdl
——
分子量
168.216
InChiKey
OUGRJASIBYFPRJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    27.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-methoxybenzenecarbothioic acid 在 potassium hydroxide 、 hydroxylamine-O-sulfonic acid 作用下, 以 二氯甲烷 为溶剂, 反应 12.08h, 生成 S-benzamido 2-methoxybenzenecarbothioate
    参考文献:
    名称:
    Design, Synthesis, and Cardioprotective Effects of N-Mercapto-Based Hydrogen Sulfide Donors
    摘要:
    Hydrogen sulfide (H2S) is a signaling molecule which plays regulatory roles in many physiological and/or pathological processes. Therefore, regulation of H2S levels could have great potential therapeutic value. In this work, we report the design, synthesis, and evaluation of a class of N-mercapto (N-SH)-based H2S donors. Thirty-three donors were synthesized and tested. Our results indicated that controllable H2S release from these donors could be achieved upon structural modifications. Selected donors (NSHD-1, NSHD-2, and NSHD-6) were tested in cellular models of oxidative damage and showed significant cytoprotective effects. Moreover, NSHD-1 and NSHD-2 were also found to exhibit potent protective effects in a murine model of myocardial ischemia reperfusion (MI/R) injury.
    DOI:
    10.1021/acs.jmedchem.5b01033
点击查看最新优质反应信息

文献信息

  • [EN] QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS<br/>[FR] QUINAZOLINES UTILISEES COMME MODULATEURS DE CANAUX IONIQUES
    申请人:VERTEX PHARMA
    公开号:WO2004078733A1
    公开(公告)日:2004-09-16
    The present invention relates to quinazoline compounds of formula (I) useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. or a pharmaceutically acceptable derivative thereof, wherein R1, X, R3, x, and ring A are as defined in the present application.
    本发明涉及式(I)的喹唑啉化合物,其作为电压门控通道和通道的抑制剂。该发明还提供了包括本发明化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病的方法。或其药学上可接受的衍生物,其中R1、X、R3、x和环A如本申请中所定义。
  • Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
    申请人:Zhang Xiaojun
    公开号:US20070003539A1
    公开(公告)日:2007-01-04
    The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
    本发明提供了式(I)或(IV)的新型苯基甘酰衍生物:或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药,其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂,可用作药物。
  • [EN] PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS<br/>[FR] PROCÉDÉ DE PRODUCTION DE MODULATEURS DE PROTÉINE COEUR DE L'HÉPATITE B
    申请人:ASSEMBLY BIOSCIENCES INC
    公开号:WO2018169907A1
    公开(公告)日:2018-09-20
    The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
    本公开部分提供了一种制备具有对乙型肝炎病毒Cp具有变构效应的化合物(I)的过程。
  • [EN] INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES<br/>[FR] INDOLES UTILES DANS LE TRAITEMENT DE MALADIES LIEES AU RECEPTEUR D'ANDROGENE
    申请人:AKZO NOBEL NV
    公开号:WO2004041782A1
    公开(公告)日:2004-05-21
    This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula (1) wherein X is S,SO or S02; R1 is a 5- or 6-membered monocyclic, hetero- or homocyclic, saturated or unsaturated ring structure optionally substituted with one or more substituents selected from the group consisting of halogen, CN, (1C-4C)fluoroalkyl, nitro, (1C-4C)alkyl, (1C-4C)alkoxy or (1C-4C)fluoroalkoxy; R2 is 2-nitrophenyl, 2-cyanophenyl, 2-hydroxymethyl-phenyl, pyridin-2-yl, pyridin-2-yl-N-oxide, 2-benzamide, 2-benzoic acid methyl ester or 2-methoxyphenyl; R3 is H, halogen or (1C-4C)alkyl; R4 is H, OH, (1C-4C)alkoxy, or halogen; R4 is H, OH, (1C-4C)alkoxy, NH2, CN, halogen, (1C-4C)fluoroalkyl, N02, hydroxy(1C-4C)alkyl, C02H, C02(1C-6C)alkyl, or R5 is NHR6, wherein R6 is (1C-6C)acyl optionally substituted with one or more halogens, S(O)2(1C-4C)alkyl, or S(O)2aryl optionally substituted with (1C-4C)alkyl or one or more halogens, or R5 is C(O)N(R8,R9), wherein R8 and R9 each independently are H, (3C-6C)cycloalkyl, or CH2R10, wherein R10 is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-4C)alkylester of carboxy(1C-4C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, (mono- or di(1C-4C)alkyl)aminomethyl, (mono- or di(1C-4C)alkyl)aminocarbonyl, or a 3-, 4-, 5- or 6-membered monocyclic, homo- or heterocyclic, aromatic or non-aromatic ring, or R8 and R9 form together with the N a heterocyclic 5- or 6-membered saturated or unsaturated ring optionally substituted with (1C-4C)alkyl; or a salt or hydrate form thereof.
    这项发明提供了与雄激素受体亲和力及用于雄激素受体相关治疗的非甾体化合物,其结构符合以下式(1):其中X为S、SO或S02;R1为5-或6-成员单环、杂环或同环、饱和或不饱和环结构,可选地取代一个或多个取代基,所选取代基包括卤素、CN、(1C-4C)氟烷基、硝基、(1C-4C)烷基、(1C-4C)氧烷基或(1C-4C)氟烷氧基;R2为2-硝基苯基、2-苯基、2-羟甲基苯基、吡啶-2-基、吡啶-2-基-N-氧化物、2-苯甲酰胺基、2-苯甲酸甲酯或2-甲氧基苯基;R3为H、卤素或(1C-4C)烷基;R4为H、OH、(1C-4C)氧烷基或卤素;R4为H、OH、(1C-4C)氧烷基、NH2、CN、卤素、(1C-4C)氟烷基、N02、羟基(1C-4C)烷基、C02H、C02(1C-6C)烷基,或R5为NHR6,其中R6为(1C-6C)酰基,可选地取代一个或多个卤素、S(O)2(1C-4C)烷基,或S(O)2芳基,可选地取代(1C-4C)烷基或一个或多个卤素,或R5为C(O)N(R8,R9),其中R8和R9各自独立地为H、(3C-6C)环烷基,或CH2R10,其中R10为H、(1C-5C)烷基、(1C-5C)烯基、羟基(1C-3C)烷基、(1C-4C)烷酯基或羧基(1C-4C)烷基、(1C-3C)氧烷基(1C-3C)烷基,(单-或双(1C-4C)烷基)基甲基,(单-或双(1C-4C)烷基)基甲酰基,或3-、4-、5-或6-成员单环、同或异环、芳香或非芳香环,或R8和R9与N一起形成一个饱和或不饱和的5-或6-成员杂环,可选地取代(1C-4C)烷基;或其盐或合物形式。
  • One-pot four-component synthesis of polysubstituted thiazoles via cascade Ugi/Wittig cyclization starting from odorless Isocyano(triphenylphosphoranylidene)-acetates
    作者:Zhi-Rong Guan、Zi-Ming Liu、Qin Wan、Ming-Wu Ding
    DOI:10.1016/j.tet.2020.131101
    日期:2020.4
    A new one-pot four-component preparation of polysubstituted thiazoles by a cascade Ugi/Wittig cyclization has been developed. The four-component reactions of the odorless isocyano(triphenylphosphoranylidene)acetates 1, aldehydes 2, amines 3 and thiocarboxylic acids 4 produced 2,4,5-trisubstituted thiazoles 5 in moderate to good yields in the presence of triethylamine. The two-component reactions between
    通过级联的Ugi / Wittig环化反应,开发了一种新的单锅四组分多取代噻唑制剂。在三乙胺的存在下,无味的异基(三苯基正膦亚基)乙酸酯1,醛2,胺3和羧酸4的四组分反应以中等至良好的产率产生了2,4,5-三取代的噻唑5。异(三苯基亚正膦)之间的双组分反应乙酸盐1个羧酸4在三乙胺的存在提供了相应的4,5 -二取代的噻唑6以良好的收率,以及。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫